Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021
Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021
dc.contributor.author | Rosadas, Carolina | |
dc.contributor.author | Costa, Milene | |
dc.contributor.author | Senna, Kátia | |
dc.contributor.author | Santos, Marisa | |
dc.contributor.author | Taylor, Graham P | |
dc.date.accessioned | 2025-02-06T15:22:56Z | |
dc.date.available | 2025-02-06T15:22:56Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Background: Human T-cell lymphotropic virus type 1 (HTLV-1) is a neglected virus that can cause severe dis- ease and be transmitted from mother to child through breastfeeding. Avoidance of breastfeeding prevents 80% of vertical transmission. The United Kingdom (UK) is currently assessing whether HTLV-1-targeted antenatal screening should be implemented. Aim: We aimed to assess the impact and cost-effectiveness of a targeted programme to prevent HTLV-1 vertical trans- mission in England and Wales. Methods: We estimated the number of pregnant women who have high risk of HTLV-1 infection based on their or their partner’s country of birth. With data from 2021, we used a math- ematical model to assess cost-effectiveness of HTLV-1 antenatal screening. We also estimated the annual number of infant infections and the number that could be prevented with screening and intervention. Results: We estimate that ca 99,000 pregnant women in England and Wales have high risk of HTLV-1 infec- tion. In the absence of screening, 74 (range: 25–211) HTLV-1 infections in infants would be expected to occur every year in England and Wales. Implementation of targeted screening would prevent 58 (range: 19–164) infant infections annually. The intervention is effec- tive (incremental 0.00333 quality-adjusted life years (QALY)) and cost-saving (GBP −57.56 (EUR −66.85)). Conclusion: Our findings support implementation of HTLV-1 targeted antenatal screening to reduce vertical transmission from mothers to infants in the UK. | |
dc.identifier.citation | Rosadas C, Costa M, Senna K, Santos M, Taylor GP. Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021. Euro Surveill. 2024 May;29(22):2300537. doi: 10.2807/1560-7917.ES.2024.29.22.2300537. | |
dc.identifier.other | DOI: 10.2807/1560-7917.ES.2024.29.22.2300537 | |
dc.identifier.uri | https://dspace.inc.saude.gov.br/handle/123456789/810 | |
dc.language.iso | en | |
dc.publisher | Euro Surveillance | |
dc.subject | HTLV | en |
dc.subject | antenatal screening | en |
dc.subject | cost-utility analysis | en |
dc.subject | economic analysis | en |
dc.subject | maternal health | en |
dc.subject | mother-to-child transmission | en |
dc.subject | prevention | en |
dc.subject | vertical transmission. | en |
dc.title | Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021 | |
dc.type | Article |